Fig. 1
From: Identification of a novel TOP2B::AFF2 fusion gene in B-cell acute lymphoblastic leukemia
Clinical data of the patient. (A) Bone marrow morphology assessed at key timepoints: diagnosis (2021.2.22), day 19 (2021.3.13), day 46 (2021.4.12), and the most recent follow-up (2023.11.23). (B) Trends in blood count parameters (WBC white blood count, ALC absolute lymphocyte count, Hb Hemoglobin, PLT platelet count) following the diagnosis of B-ALL. The horizontal shaded areas indicate age-specific normal reference ranges for each parameter, reflecting the expected values for healthy individuals based on established pediatric reference intervals. (C) Clinical follow-up monitoring bone marrow (BM) blast percentages and measurable residual disease (MRD) using flow cytometry at diagnosis, day 19, day 46, and the most recent follow-up. (D) G-banding analysis of bone marrow cells showing a cytogenetic profile of 46, XX.
